Reports Q1 revenue $23.19M, consensus $25.96M. “During the first quarter, Lifecore (LFCR) continued to successfully execute the three pillars of its growth strategy – maximizing our existing commercial business, advancing our development pipeline toward commercialization, and adding high-quality, new programs to our pipeline through business development. We believe our continued execution across these pillars positions Lifecore for sustained growth, including our goal of achieving a 12% revenue CAGR and EBITDA margins above 25% by the end of 2029. In the near-term, we remain confident in our full-year expectations and reaffirm our 2026 guidance.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Analyst Reiterates Buy on Lifecore Despite Weak Q1, Citing Confidence in 2026 Targets and Attractive Risk-Reward
- Lifecore price target raised to $6 from $5.50 at Barrington
- Lifecore management to meet with Barrington
- Is LFCR a Buy, Before Earnings?
- Lifecore Biomedical Earnings Call Signals Profitable Shift
